v3.25.2
GeneFab Transaction (Details) - USD ($)
Aug. 07, 2023
Jun. 30, 2025
Jan. 31, 2025
Dec. 31, 2024
Dec. 10, 2024
Contingent Consideration Receivable | Level 3          
Related Party Transaction [Line Items]          
Fair value of asset $ 1,800,000        
GeneFab          
Related Party Transaction [Line Items]          
Prepayments for manufacturing and research activities $ 18,900,000        
Additional advance payment commitment   $ 2,500,000     $ 10,000,000
Additional advance paid     $ 4,000,000 $ 6,000,000  
Additional advance payment commitment, remaining amount   5,500,000      
Revenue, remaining performance obligation, variable consideration, realized gains (in percent) 10.00%        
Consideration received in collaborative development agreement $ 37,800,000        
Upfront payment under research collaboration and license agreement 18,900,000        
Variable consideration 18,900,000        
Notes receivable at fair value $ 16,600,000        
Option, maximum purchase amount (in shares) 1,963,344        
Option, maximum worth $ 20,000,000.0        
Option, exercise price (in dollars per share) $ 10.18670        
Option, installments, percentage of stock outstanding (in percent) 19.90%        
GeneFab | Contingent Consideration Receivable | Level 3          
Related Party Transaction [Line Items]          
Fair value of asset   0   0  
GeneFab | Equity Option          
Related Party Transaction [Line Items]          
Derivative liability $ 9,600,000        
GeneFab | Equity Option | Level 3 | Derivative Financial Instruments, Liabilities          
Related Party Transaction [Line Items]          
Fair value of liability   $ 0   $ 0